Clinical Trial: Durvalumab combined with S-1 as adjuvant therapy for resectable Biliary Tract Cancer (China)

China, Nov. 3 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Durvalumab combined with S-1 as adjuvant therapy for resectable Biliary Tract Cancer'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600135743

Registration Time: 2026/11/02

Type: Interventional study

Primary Sponsor: Cancer Hospital Chinese Academy of Medical Sciences

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=305613

Published by HT Digital Content Services with permission from Health Daily Digest....